The impact of indirect government controls on U.S. drug prices and R&D

Cato Journal

Volumn 26, Issue 1, 2006, Pages 143-158

  Santerre, Rexford E ^a   Vernon, John A ^a   Giaccotto, Carmelo ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645778026     PISSN: 02733072     EISSN: 02733072     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Comanor, W. S. (1986) "The Political Economy of the Pharmaceutical Industry." Journal of Economic Literature 24 (3): 1178-1217.
2. DHHS (1994) "Prescription Drugs: Spending Controls in Four European Countries." Department of Health and Human Services, Washington, D.C., HEHS-94-30.
3. DiMasi, J. A.; Hansen, R. W.; and Grabowski, H. G. (2003) "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics 22: 151-85.
4. Duggan, M., and Scott Morton, F. M. (2004) "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing." NBER Working Paper No. W10930. National Bureau of Economic Research, Cambridge, Mass. (November).
5. Giaccotto, C.; Santerre, R. E.; and Vernon, J. A. (2005) "Pharmaceutical Pricing and R&D Growth Rates." Journal of Law and Economics 48 (1): 195-214.
6. Granger, C. W., and Newbold, P. (1974) "Spurious Regressions in Econometrics." Journal of Econometrics 2: 111-20.
7. Grabowski, H. G., and Vernon, J. M. (2000) "The Determinants of Pharmaceutical Research and Development Expenditures." Journal of Evolutionary Economics 10: 201-15.
8. Hausman, J. (2003) "Sources of Bias and Solutions to Bias in the Consumer Price Index." Journal of Economic Perspectives 17 (1): 23-44.
9. Hughes, J. W.; Moore, M. J.; and Snyder, E. A. (2002) "Napsterizirig Pharmaceuticals: Access, Innovation, and Consumer Welfare. NBER Working Paper No. 9229.
10. Lichtenberg, F. R. (2002) "Sources of U. S. Longevity Increase, 1960-1997." NBER Working Paper No. 8755.
11. Murphy, K., and Topel, R. (2003) Measuring the Gains from Medical Research. Chicago: University of Chicago Press.
12. Oberlander, J. (2003) "Medicare and the Politics of Prescription Drug Pricing." North Carolina Medical Journal 64 (6): 303-4.
13. Pear, R. (1993) "Clinton Backs Off Drug Price Limits." New York Times, as printed by San Jose Mercury News (17 May).
14. Phillips, P. C. (1986) "Understanding Spurious Regressions in Econometrics. "Journal of Econometrics 33: 311-40.
15. Republican Policy Committee (2004) "Competition vs. Price Controls: The Road to Lower Prescription Drug Prices." Washington: United States Senate (9 March): 1-7.
16. Scherer, F. M. (1996) Industry Structure, Strategy, and Public Policy. New York: Harper Collins.
17. Scherer, F. M., and Ross, D. (1990) Industrial Market Structure and Economic Performance. Boston: Houghton Mifflin.
18. Schwartzman, D. (1976) Innovation in the Pharmaceutical Industry. Baltimore: Johns Hopkins University Press.
19. Scott Morton, F. M. (1997) "The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules." Rand Journal of Economics 28 (2): 269-90.
20. Vernon, J. A. (2004) "Simulating the Impact of Price Regulation on Pharmaceutical Innovation." Pharmaceutical Development and Regulation 1(1): 55-65.
21. _ (2005) "Examining the Link Between Price Regulation and Pharmaceutical R&D Investment." Health Economics 14:1-16.